Cheng Andrew's Form 4 filing
Akero Therapeutics, Inc. (AKRO) · filed Sep 12, 2025
- Accession no.
- 0000950170-25-114661
- Filed
- Sep 12, 2025
- Trade date
- Sep 10-11, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.37M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cheng AndrewCIK 0001778307 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | Common Stock | MOption exerciseAcquired | +13,022 | $6.36 | +$82,819.92 | 503,779 | Direct | |
| Sep 10, 2025 | Common Stock | MOption exerciseAcquired | +1,919 | $19.87 | +$38,130.53 | 505,698 | Direct | |
| Sep 10, 2025 | Common Stock | SSaleDisposed | −22,525 | $42.99 | −$968,349.75 | 483,173 | Direct | |
| Sep 10, 2025 | Common Stock | SSaleDisposed | −7,317 | $44.00 | −$321,948 | 475,856 | Direct | |
| Sep 10, 2025 | Common Stock | SSaleDisposed | −158 | $44.62 | −$7,049.96 | 475,698 | Direct | |
| Sep 11, 2025 | Common Stock | SSaleDisposed | −1,796 | $43.02 | −$77,263.92 | 473,902 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | Common Stock | MOption exerciseDisposed | −13,022 | $0.00 | $0 | 0 | Direct | |
| Sep 10, 2025 | Common Stock | MOption exerciseDisposed | −1,919 | $0.00 | $0 | 410,017 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.